Annemie R.
- Country
- Belgium
- Department
- 3001:Oncologie
Research Overview
- A Phase 3, Randomized, Double-blind, Active-Comparator-Controlled Clinical Study of Adjuvant MK-7684A (Vibostolimab with Pembrolizumab) Versus Adjuvant Pembrolizumab in Participants with High-risk Stage II-IV Melanoma (KEYVIBE-010)
- Adjuvant Therapy with Pembrolizumab versus Placebo in Resected Highrisk Stage II Melanoma: A Randomized, Double-blind Phase 3 Study (KEYNOTE 716)
- Efficacy and Safety Evaluation of Naporafenib Combinations in Previously Treated Unresectable or Metastatic BRAFV600/NRAS Mutant Melanoma
Data & Insights
Has run more than one trial at 74 of 154 partner sites.
Specializations
Melanoma Research
The investigator specializes in the treatment of advanced melanoma, with particular focus on adjuvant therapy approaches for different disease stages.
- High-risk Stage II melanoma management
- Stage III/IV melanoma treatment
- BRAF and NRAS mutant melanoma
Their research encompasses innovative therapeutic strategies for both resectable and metastatic disease states.
Immunotherapy
The investigator conducts research in novel immunotherapeutic approaches, particularly focusing on combination treatments and monotherapy applications.
- Checkpoint inhibitor therapy
- Fixed-dose combination treatments
- Post-surgical immunotherapy
Their work includes evaluation of various immunotherapy combinations for optimal treatment outcomes.
Bladder Cancer
The investigator explores treatments for muscle-invasive bladder cancer, with emphasis on neoadjuvant therapy approaches.
- Combined chemotherapy protocols
- Pre-surgical treatment strategies
- Post-radical cystectomy therapy
Their research includes investigation of innovative therapeutic combinations for bladder cancer treatment.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.